USA: Business Strategy Seqens Announces Multi-Million-Dollar Investment in R&D Laboratory
Seqens has made the mega investment in its U.S. laboratory located in Devens, Massachusetts. With this move, the company aims to increase its R&D capability and productivity in the U.S. as well as strengthen its global R&D network.
Écully/France – Seqens, an integrated leader in the manufacturing of active ingredients and pharmaceutical intermediates, has recently announced a multi-million-dollar investment in its research and development laboratory located in Devens, Massachusetts, USA. The improvements will ensure that the new facility will operate at the highest standards of safety and quality, while also increasing the company’s R&D capability and productivity in the US strengthening its global R&D network. Completion of the project is expected in October 2022.
The investment in Devens strengthens the company’s U.S. operations—which also includes a sales office and contract development and manufacturing operation in nearby Newburyport, Mass.—and signals the firm’s commitment to broadening its reach in the U.S. market. The investment comes just three months after SK Capital became a majority holder in Seqens by merging it with its portfolio company Wavelength Pharmaceuticals to create one of the largest, most diversified contract development and manufacturing organizations (CDMOs) in the world.
New investors in Seqens, alongside SK Capital, include Bpifrance and Nov Santé, with existing shareholders Mérieux Equity Partners, Ardian, and Eximium.